Results 231 to 240 of about 180,189 (308)

Decreasing Microtubule Detyrosination Improves Cardiac Mechanics and Sodium Channel Function in Arrhythmogenic Cardiomyopathy. [PDF]

Circ Arrhythm Electrophysiol
Nasilli G, Lin X, Swiatlowska P, Meraviglia V, Pérez-Hernández M, Zhang M, Sanchez-Alonso JL, Bellin M, Gorelik J, Rothenberg E, Casini S, Delmar M, Remme CA.   +12 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Maternal hyperglycemia-induced O-GlcNAcylation of CaMKIIδ promotes mtDNA release and cardiac remodeling in offspring. [PDF]

Nat Commun
Xiao Z, Gao L, Wang Y, Yang C, Qian Y, Chen L, Li X, Geng N, Chen T, Yuan A, Hu L, Thai PN, Li H, Gao L, Xu Z, Lu X, Pu J.   +16 more
europepmc   +1 more source

c-Myc: an emerging participant in heart failure. [PDF]

Front Cardiovasc Med
Wu Y, Zhang J, Liu R, Lin W, Wang W, Zhao Y, Cai Y, Su H, Sun W, Zhu H, Zhao M, Chang P.   +11 more
europepmc   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Organelle network dysfunction in primary cardiomyopathy: An integrated perspective on pathogenesis and therapeutics. [PDF]

J Mol Cell Cardiol Plus
Pu S, Yang P.
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

A Scalable MNase-seq Framework for Reproducible Nucleosome Profiling across Pluripotent Stem Cell and Cardiomyocyte Models. [PDF]

Comput Struct Biotechnol J
Thekkedam C, Humphreys DT, Naval-Sanchez M, Nicks AM, Harvey RP, Contreras O.   +5 more
europepmc   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

MLL4 protects cardiomyocytes against ischemia-reperfusion injury through STAT3-mediated mitochondrial function. [PDF]

Redox Biol
Pang QY, Meng XM, Li DY, You L, Zhou ZF, Li YM, Deng T, Yuan JH, Li H, Feng QP, Zhu BM.   +10 more
europepmc   +1 more source